Neurogene Inc. Files 8-K on Security Holder Vote

TL;DR

Neurogene filed an 8-K for a shareholder vote on June 14th.

AI Summary

Neurogene Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders on June 14, 2024. The company, formerly known as Neoleukin Therapeutics, Inc., is based in New York, NY.

Why It Matters

This filing indicates important corporate actions or decisions requiring shareholder approval, which could impact the company's future direction and stock performance.

Risk Assessment

Risk Level: low — This is a routine filing reporting on a shareholder vote, not indicating immediate financial distress or significant operational changes.

Key Players & Entities

• Neurogene Inc. (company) — Registrant
• Neoleukin Therapeutics, Inc. (company) — Former company name
• June 14, 2024 (date) — Date of earliest event reported
• June 17, 2024 (date) — Date of report

FAQ

Key Financial Figures

• $0.000001 — ange on which registered Common Stock, $0.000001 par value NGNE The Nasdaq Global Market

Filing Documents

• ngne-20240614.htm (8-K) — 34KB
• 0001404644-24-000066.txt ( ) — 158KB
• ngne-20240614.xsd (EX-101.SCH) — 2KB
• ngne-20240614_lab.xml (EX-101.LAB) — 22KB
• ngne-20240614_pre.xml (EX-101.PRE) — 13KB
• ngne-20240614_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders On June 14, 2024, Neurogene Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), at which the matters listed below were presented. There were 9,829,572 shares of common stock present at the Annual Meeting in person or by proxy, which represented approximately 76.40 % of the voting power of the shares of common stock entitled to vote at the Annual Meeting and constituted a quorum for the transaction of business. Holders of the Company's common stock were entitled to one vote for each share held as of the close of business on April 18, 2024. A more detailed description of each of the proposals is included in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 26, 2024. The final voting results are set forth below. 1. Election of two Class I directors, Cory Freedland and Rachel McMinn, each to serve until the 2027 annual meeting of stockholders and until their respective successors are elected and qualified: Nominee Shares For Shares Withheld Broker Non-Votes Cory Freedland 9,198,010 382,881 248,681 Rachel McMinn 9,198,031 382,860 248,681 2. Approval on an advisory (non-binding) basis of the compensation of the Company's named executive officers: Shares For Shares Against Shares Abstaining Broker Non-Votes 9,092,990 482,023 5,878 248,681 3. Ratification on an advisory (non-binding) basis of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting rm for the year ending December 31, 2024: Shares For Shares Against Shares Abstaining 9,826,384 1,361 1,827 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: June 17, 2024 By: /s/ Christine Mikail Name: Christine Mikail Tit

View Full Filing

View this 8-K filing on SEC EDGAR